ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin

Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors

NAVRKALOVÁ Veronika ŠEBEJOVÁ Ludmila ZEMANOVÁ Jana KMÍNKOVÁ Jana KUBEŠOVÁ Blanka MALČÍKOVÁ Jitka MRÁZ Marek ŠMARDOVÁ Jana PAVLOVÁ Šárka DOUBEK Michael BRYCHTOVÁ Yvona POTĚŠIL David NÉMETHOVÁ Veronika MAYER Jiří POSPÍŠILOVÁ Šárka TRBUŠEK Martin

Year of publication 2013
Type Article in Periodical
Magazine / Source Haematologica
MU Faculty or unit

Central European Institute of Technology

Citation
Doi http://dx.doi.org/10.3324/haematol.2012.081620
Field Oncology and hematology
Keywords ATM mutations; CLL; ATM dysfunction; doxorubicin
Attached files
Description ATM abnormalities are frequent in chronic lymphocytic leukemia and represent an important prognostic factor. Sole 11q deletion does not result in ATM inactivation by contrast to biallelic defects involving mutations. Therefore, the analysis of ATM mutations and their functional impact is crucial. In this study, we analyzed ATM mutations in predominantly high-risk patients using: i) resequencing microarray and direct sequencing; ii) Western blot for total ATM level; iii) functional test based on p21 gene induction after parallel treatment of leukemic cells with fludarabine and doxorubicin. ATM dysfunction leads to impaired p21 induction after doxorubicin exposure. We detected ATM mutation in 16% (22 of 140) of patients, and all mutated samples manifested demonstrable ATM defect (impaired p21 upregulation after doxorubicin and/or null protein level). Loss of ATM function in mutated samples was also evidenced through defective p53 pathway activation after ionizing radiation exposure. ATM mutation frequency was 34% in patients with 11q deletion, 4% in the TP53-defected group, and 8% in wild-type patients. Our functional test, convenient for routine use, showed high sensitivity (80%) and specificity (97%) for ATM mutations prediction. Only cells with ATM mutation, but not those with sole 11q deletion, were resistant to doxorubicin. As far as fludarabine is concerned, this difference was not observed. Interestingly, patients from both these groups experienced nearly identical time to first treatment. In conclusion, ATM mutations either alone or in combination with 11q deletion uniformly led to demonstrable ATM dysfunction in patients with chronic lymphocytic leukemia and mutation presence can be predicted by the functional test using doxorubicin.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info